---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-056484"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:47:37.657841+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NextCure reports Q1 2022 net loss of $20.6M; cash at $201.3M, runway into Q1 2024

## Summary
- Net loss of $20.6M vs $16.5M in Q1 2021, driven by higher R&D expenses.
- Cash, cash equivalents and securities of $201.3M, down $18.3M from Dec 2021.
- On track for H2 2022 milestones: NC318 Phase 2 update, NC410 Phase 1 update, NC762 initial data, NC525 IND filing.
- Cash expected to fund operations into Q1 2024.
- R&D expenses $15.0M (Q1 2022) vs $12.4M (Q1 2021); G&A $5.8M vs $4.9M.

## SEC filing metadata
- accession: 0001104659-22-056484
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465922056484/0001104659-22-056484-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465922056484/tm2214609d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-056484
- JSON: https://secwatch.observer/filing/0001104659-22-056484.json
- Plain text: https://secwatch.observer/filing/0001104659-22-056484.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.